Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with Mycophenolate Mofetil

  title={Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with Mycophenolate Mofetil},
  author={Aliya F. Gulamhusein and Janet E. Pope},
  journal={The Journal of Rheumatology},
  pages={460 - 461}
Systemic sclerosis (SSc) is a rare multisystem connective tissue disease of unclear etiology in which vascular dysfunction, fibrosis of the skin and internal organs, and autoimmunity occur. Until recently, few treatments have been successful at reducing mortality associated with the disease. The use of angiotensin-converting enzyme (ACE) inhibitors and targeted therapies such as endothelin receptor antagonists, prostacyclins, and PDE5 inhibitors have improved outcomes with respect to renal… Expand
Systemic Sclerosis and Malignancy: A Review of Current Data
The lack of a concretely defined high-risk profile and the absence of malignancy screening guidelines tailored for SSc patients raise the importance of the need for more studies on the association of SSc and cancer and should incite rheumatology colleges to develop specific recommendations for the clinician to follow while approaching patients with SSc. Expand
Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review
Observational data suggests mycophenolate may be effective in improving or stabilizing interstitial lung disease, and skin involvement, but not severe enough to preclude its use. Expand
Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors
Light is shed on the potential relationship between cancer and scleroderma regarding temporal and immunological dimensions and on the most recent articles on this topic. Expand
Novel risk factors related to cancer in scleroderma.
PM/Scl antibodies seem to be associated with a higher risk of cancer in scleroderma, and the use of aspirin is related to a lower risk ofcancer in the authors' series. Expand
Mechanistic and clinical insights at the scleroderma-cancer interface
Data suggesting a mechanistic link between cancer and the development of scleroderma is discussed, and the clinical implications of these findings are discussed. Expand
Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia
The mechanisms by which immunosuppressive drugs can influence neoplasia are outlined, the available preclinical data on the 13 drugs are summarized, and the performance of the models are critically reviewed. Expand
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
A significant association was observed between the use of immunosuppressive therapy and diffuse skin extension, negative ACA, positive Anti-Scl-70, and interstitial lung disease, but not BC status, suggesting a de-escalation strategy of cancer therapies. Expand
Association between systemic sclerosis and risk of lung Cancer: Results from a Pool of cohort studies and Mendelian randomization analysis.
This study indicated an increased risk of lung cancer among patients with SSc by meta-analysis, whereas two-sample Mendelian randomization study did not support a causality between the two diseases. Expand


Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
MMF is very well tolerated and appears to be at least as effective as the other current therapies for dcSSc, and provides support for further evaluation of MMF in a prospective trial. Expand
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
The preliminary data suggest that in patients with dSSc and recent, clinically apparent alveolitis, early treatment with MMF and small doses of corticosteroids (CS) may represent an effective, well-tolerated and safe alternative therapy. Expand
New developments in the pathogenesis of systemic sclerosis
Medications directed against immune cells or harmful soluble factors in small trials in SSc are encouraging, and new developments have direct impact on the treatment of SSc. Expand
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.
ATG and MMF appear safe in scleroderma and the improvement in skin score and the apparent stability of systemic disease during the study period suggest that controlled studies of these agents are justified. Expand
Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis
New insights have direct impact on the treatment of patients with systemic sclerosis; therapies that target T cells, B cells and their harmful mediators are a logical approach, and preliminary data are promising. Expand
Mechanisms of action of mycophenolate mofetil
Evidence is accumulating that MMF may have clinical utility in some autoimmune disorders, and it is suggested that it reduces acute and chronic rejection in allograft recipients and is efficacious in some nephropathies. Expand
Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review.
The use of MMF is associated with slight increases in gastrointestinal adverse effects, some hematologic adverse events, and CMV infections compared with Aza, and larger sample sizes of randomized controlled trials are needed. Expand
Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre‐transplant diabetes
Treatment with MMF compared with treatment with AZA in diabetic transplant patients is associated with less AR, less risk of LAR, a decreased risk of CV death, and a lower incidence of malignancies. Expand
Malignancy after Transplantation
Although calcineurin inhibitors and azathioprine have been linked with posttransplant malignancies, newer agents such as mycophenolate mofetil and sirolimus have not and indeed may have antitumor properties and long-term data are needed to determine if the use of these agents will ultimately lower the mortality due to malignancy for transplant recipients. Expand
Clinically Relevant Immunosuppressants Influence UVB‐Induced Tumor Size Through Effects on Inflammation and Angiogenesis
  • F. J. Duncan, Brian C. Wulff, +7 authors A. Vanbuskirk
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
The choice of immunosuppressants has important implications for tumor number, size and progression, likely due to the influence of immunOSuppressant effects on UVB‐induced inflammation and angiogenesis. Expand